How Tolerable is Pembrolizumab/Paclitaxel/Bevacizumab in PROC? | CancerNetwork
How Tolerable is Pembrolizumab/Paclitaxel/Bevacizumab in PROC? | CancerNetwork
2 months ago
cancernetwork.com
Understanding the Pembrolizumab Treatment Combo in Platinum-Resistant Ovarian Cancers | Oncology Nursing News
Understanding the Pembrolizumab Treatment Combo in Platinum-Resistant Ovarian Cancers | Oncology Nursing News
2 months ago
oncnursingnews.com
Lenvatinib Plus Pembrolizumab in Endometrial Cancer After Neoadjuvant/Adjuvant Therapy | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Lenvatinib Plus Pembrolizumab in Endometrial Cancer After Neoadjuvant/Adjuvant Therapy | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
3 months ago
targetedonc.com
Dr Zhou on Frontline Ivonescimab vs Pembrolizumab in PD-L1 Advanced NSCLC | OncLive
Dr Zhou on Frontline Ivonescimab vs Pembrolizumab in PD-L1 Advanced NSCLC | OncLive
Mar 3, 2025
onclive.com
Dr Ashraf on Ivonescimab vs Pembrolizumab as a First-Line Treatment for PD-L1 Advanced NSCLC | OncLive
Dr Ashraf on Ivonescimab vs Pembrolizumab as a First-Line Treatment for PD-L1 Advanced NSCLC | OncLive
Oct 14, 2024
onclive.com
Everett E. Vokes, MD, FASCO, from UChicago Medicine presents interim results from a phase 3 trial comparing petosemtamab plus pembrolizumab versus pembrolizumab monotherapy for first-line treatment of recurrent/metastatic PD-L1-positive head and neck squamous cell carcinoma. Watch more here: https://www.onclive.com/view/petosemtamab-plus-pembrolizumab-vs-pembrolizumab-alone-for-first-line-1l-treatment-of-recurrent-metastatic-r-m-pd-l1-positive-head-and-neck-squamous-cell-carcinoma-hnscc-a-random
1:42
Everett E. Vokes, MD, FASCO, from UChicago Medicine presents interim results from a phase 3 trial comparing petosemtamab plus pembrolizumab versus pembrolizumab monotherapy for first-line treatment of recurrent/metastatic PD-L1-positive head and neck squamous cell carcinoma. Watch more here: https://www.onclive.com/view/petosemtamab-plus-pembrolizumab-vs-pembrolizumab-alone-for-first-line-1l-treatment-of-recurrent-metastatic-r-m-pd-l1-positive-head-and-neck-squamous-cell-carcinoma-hnscc-a-random
64 viewsJan 6, 2025
FacebookOncLive
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial | OncLive
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial | OncLive
Sep 27, 2024
onclive.com
Chemotherapy Pembrolizumab: A New Standard of Care? | OncLive
Jul 10, 2018
onclive.com
ESMO 2024 Summary: Evaluation of Ivonescimab CT and PM8002/BNT327 Nab-Paclitaxel for 1L TNBC: Results From Two Studies
192 viewsOct 1, 2024
vumedi.com
Comparing Nivolumab and Pembrolizumab in the Treatment of Lung Cancer | Cancer
Aug 12, 2020
labroots.com
Pembrolizumab Alone or Combined With Chemotherapy vs Chemotherapy As First-Line Therapy for Advanced Urothelial Carcinoma in the KEYNOTE-361 Trial Journal Club – Christopher Wallis & Zachary Klaassen
9 months ago
urotoday.com
Summit Therapeutics Announces Clinical Trial Collaboration with GSK plc to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate
3 months ago
marketscreener.com
Dr Riess on the Investigation of Ivonescimab in Advanced NSCLC | OncLive
Jan 9, 2025
onclive.com
Akeso, Inc. Announces Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC Presented atESMO IO 2025
4 months ago
marketscreener.com
KEYNOTE-522: Neoadjuvant and Adjuvant Pembrolizumab in TNBC | OncLive
Jun 1, 2022
onclive.com
ASCO® 2024 Insights: "HARMONi-A Trial - Ivonescimab Combined With Chemo in Patients With EGFRm non-Squamous NSCLC Who Progressed on EGFR-TKI Treatment"
135 viewsJun 17, 2024
vumedi.com
Dr. Vokes on Selecting Nivolumab or Pembrolizumab for Head and Neck Cancer Treatment | OncLive
Dec 28, 2016
onclive.com
NICE recommends pembrolizumab for 1,600 more people with breast cancer - Cancer Research UK - Cancer News
Nov 14, 2022
cancerresearchuk.org
ASCO® 2024 Insights: "HARMONi-A Study - Ivonescimab Chemo for EGFRm NSCLC Patients Who Progressed on EGFR-TKI Treatment"
35 viewsJul 2, 2024
vumedi.com
Akeso, Inc.: NMPA Accepts sNDA for Ivonescimab in Combination with Chemotherapy as First-Line Treatment for Advanced Squamous Non-Small Cell Lung Cancer
5 months ago
finanznachrichten.de
Akeso, Inc.: Akeso Highlights Collaboration Between Its Partner Summit Therapeutics and Pfizer to Explore Ivonescimab in Combination with Pfizer's ADCs
Feb 25, 2025
finanznachrichten.de
Choosing Between Atezolizumab and Pembrolizumab in Lung Cancer | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Jul 2, 2018
targetedonc.com
42:48
Immunotherapy for Lung Cancer
14.7K viewsJan 18, 2016
YouTubeGlobal Resource for Advancing Cancer Education
6:11
Pembrolizumab: Monotherapy Versus Combination Therapy
764 viewsJun 29, 2018
YouTubeOncLive
3:20
How Monoclonal Antibodies Treat Cancer
174.1K viewsJun 30, 2020
YouTubeNational Cancer Institute
3:12
Opdivo (nivolumab) the Immunotherapy Cancer Treatment
81K viewsJun 3, 2016
YouTubeOncology Associates
4:22
Nivolumab in Non-Small Cell Lung Cancer
7.9K viewsNov 22, 2014
YouTubeOncLive
3:01
Choosing Between Atezolizumab and Pembrolizumab in Lung Cancer
6.7K viewsJul 2, 2018
YouTubeTargeted Oncology
2:05
Pembrolizumab as Second-line Therapy for Advanced Urothelial Carcinoma
11.5K viewsMar 16, 2017
YouTubeNEJM Group
1:39
Pembrolizumab/Lenvatinib Combo Achieves Promising Responses in Anaplastic Thyroid Cancer
1.2K viewsSep 19, 2020
YouTubeTargeted Oncology
See more